REVIEW PAPER
The role of natural killer cells in pathogenesis of autoimmune diseases
Submission date: 2015-11-10
Acceptance date: 2015-11-19
Publication date: 2016-01-15
Cent Eur J Immunol 2015;40(4):470-476
KEYWORDS
ABSTRACT
There is growing evidence that NK cell-mediated immunoregulation plays an important role in the control of autoimmunity. NK cells are a subset of lymphocytes that generally contribute to innate immunity but have also a great impact on the function of T and B lymphocytes. The major role of NK cells is cytotoxic reaction against neoplastic, infected and autoreactive cells, but they regulatory function seems to play more important role in the pathogenesis of autoimmune diseases. Numerous studies suggested the involvement of NK cells in pathogenesis of such a common autoimmune diseases as juvenile rheumatoid arthritis, type I diabetes and autoimmune thyroid diseases. The defects of NK cells regulatory function as well as cytotoxic abilities are common in patients with autoimmune diseases with serious consequences including HLH hemophagocytic lymphocytosis (HLH) and macrophage activation syndrome (MAS). The early diagnosis of NK cells defect responsible for the loss of the protective abilities is crucial for the prevention of life-threatening complications and implementation of necessary treatment.
REFERENCES (62)
1.
Freud AG, Becknell B, Roychowdhury S, et al. (2005): A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22: 295-304.
2.
Andrews DM, Smyth MJ (2010): A potential role of RAG-1 in NK cell development revealed by analysis of NK cells during ontogeny. Immunol Cell Biol 88: 107-116.
3.
Ma A, Koka R, Burkett P (2006): Diverse functions of IL-2, IL-15 and IL-7 in lymphoid homeostasis. Annu Rev Immunol 24: 657-679.
4.
Ashouri E, Dabbaghmanesh MH, Omrani GR, et al. (2014): Presence of more activating KIR genes is associated with Hashimoto’s thyroiditis. Endocrine 46: 519-525.
5.
Vilches C, Parham P (2002): KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol 20: 217-251.
6.
Mandal A, Viswanathan C (2015): Natural killers: In health and disease. Hematol Oncol Stem Cell Ther 8: 47-55.
7.
Bryceson YT, March ME, Ljunggren H-G, et al. (2006): Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166.
8.
Colonna M, Navarro F, Bellón T, et al. (1997): A common inhibitoryreceptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186: 1809-1818.
9.
Osińska I, Popko K, Demkow U (2014): Perforin: an important player in immune response. Centr Eur J Immunol 39: 109-115.
10.
Trapani JA, Smyth MJ (2002): Functional significance of the perforin/granzyme cell death pathway. Nature Review Immunol 2: 735-747.
11.
Voskoboinik I, Dunstone MA, Baran K, et al. (2010): Perforin: structure, function, and role in human immunopathology. Immunol Rev 235: 35-54.
12.
Cooper MA, Fehniger TA, Caligiuri MA (2001): The biology of human natural killer-cell subset. Trends Immunol 11: 633-640.
13.
Cooper MA, Fehniger TA, Turner SC, et al. (2001): Human natural killer cells: a unique innate immunoregulatory role for the CD56brightsubset. Blood 97: 3146-3151.
14.
Wilk E, Kallipke K, Buyny S, et al. (2008): New aspects of NK cell subset identification and inference of NK cells’ regulatory capacity by assessing functional and genomic profiles. Immunobiology 213: 271-283.
15.
Sinkonics JG, Horvath JC (2005): Human natural killer cells: a comprehensive revive. Int J Oncol 27: 5-47.
16.
French AR, Yokoyama WM (2004): Natural killer cells and autoimmunity. Arthritis Res Ther 6: 8-14.
17.
Morse RH, Seguin R, McCrea EL, et al. (2001): NK cell-mediated lysis of autologous human oligodendrocytes. J Neuroimmunol 116: 107-115.
18.
Flodstrom M, Maday A, Balakrishna D, et al. (2002): Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 3: 373-382.
19.
Linsen L, Somers V, Stinissen P (2005): Immunoregulation of autoimmunity by natural killer T cells. Human Immunology 66: 1193-1202.
20.
Fairweather D, Kaya Z, Shellam GR, et al. (2001): From infection to autoimmunity. J Autoimmun 16: 175-186.
21.
Augusto DG, Lobo-Alves SC, Melo MF, et al. (2012): Activating KIR and HLA Bw4 ligands are associated to decreased susceptibility to pemphigus foliaceus, an autoimmune blistering skin disease. PLoS ONE 7(7): e39991.
22.
HaiQing Z, JiaJun Z, YueRan Z, et al. (2009): Genotypes of killer cell immunoglobulin-like receptors in Hashimoto’s thyroiditis patients. Journal of Shandong University (Health Sciences) 47: 1-4.
23.
van der Slik AR, Alizadeh BZ, Koeleman BP, et al. (2007): Modelling KIR-HLA genotype disparities in type 1 diabetes. Tissue Antigens 69 (Suppl 1): 101-105.
24.
Niepiekło-Miniewska W, Majorczyk E, Matusiak L, et al. (2013): Protective effect of the KIR2DS1 gene in atopic dermatitis. Gene 527: 594-600.
25.
Hou Y-F, Zhang Y-C, Jiao Y-L, et al. (2010): Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus 19: 20-26.
26.
García-León JA, Pinto-Medel MJ, García-Trujillo L, et al. (2011): Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol Immunol 48: 1896-1902.
27.
Guðjónsson JE, Karason A, Antonsdottir AA, et al. (2002): HLA-Cw6-positiv and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 118: 362-365.
28.
Rodacki M, MIlech A, de Olivejra JEP, (2006): NK cell land Type 1 diabetes. Clin Dev Immunol 13: 101-107.
29.
Janeway CA, Trawers P, Walport M (2005): An introduction to immunobiology and innate immunity. NY Ed Garland Science Publishing. P. 1-35.
30.
Dalbeth N, Callan MFC (2002): A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Reum 46: 1763-1772.
31.
Pridgeon C, Lennon GP, Pazmany L, et al. (2003): Natural killer cells in the synovial fluid of rheumatoid arthritis patients exhibit CD56bright, CD94bright,CD158negative phenotype. Rheumatology 42: 870-878.
32.
de Matos CT, Berg L, Michaelsson J, et al. (2007): Activating and inhibitory receptors on synovial fluid natural killer cells of arthritis patients: role of CD94/NKG2A in control of cytokine secretion. Immunology 122: 291-301.
33.
Zhang AL, Colmenero P, Purath U, et al. (2007): Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 110: 2484-2493.
34.
Ren J, Feng Z, Lv Z, et al. (2011): Naturak killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-. J Reumatol 38: 2112-2118.
35.
Grog V, Bruhl A, El-Gabalawy H, et al. (2003): Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid artritis. Proc Natl Acad Sci U S A 100: 9452-9457.
36.
Fogel L, Yokoyama WM, French AR (2013): Natural killer cells in human autoimmune disorders. Arthitis Res Ther 15: 216-224.
37.
Aramaki T, Ida H, Izumi Y, et al. (2009): Significantly impaired natural cell activity due to a low activity on a per-cell basis in rheumatoid arthritis. Mod Rheumatol 19: 245-252.
38.
Wulffraat NM, Rijekers GT, Elst E, et al. (2003): Reduced perforin expression in systemic juvenile idiopathic arthritis is restores by autologous stem-cell transplantation. Rheumatology 42: 375-379.
39.
Grom AA, Villanueva J, Lee S, et al. (2003): Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 142: 292-296.
40.
Villanueva J, Lee S, Giannini EH, et al. (2005): Natural killer cell dysfunction is a distinguishing feature of systyemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7: R30-37.
41.
Behrens EM (2008): Macrophage activation syndrome in rheumatic disease: What is the role of the antigen presenting cell? Autoimmun Rev 7: 305-308.
42.
Anjos S, Polychronakos C (2004): Mechanisms of genetic susceptibility to 1 diabetic: beyond HLH. Mol Genet Metab 81: 357-395.
43.
Robles DT, Eisenbarth GS, (2001): Type 1A diabetes induced by infection and immunization. J Autoimmun 16355-16362.
44.
Wu YL, Ding YP, Gao Y (2013): Risk factors and primary prevention trials for type 1 diabetes. Int J Biol Sci 9: 666-679.
45.
Akerblom HK, Vaarala O, Hyoty H, et al. (2002): Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 115: 18-29.
46.
Hussain MJ, Alviggi L, Millward BA, et al. (1987): Evidence that the reduced number of natural killer cells in type 1 diabetes may be genetically determined. Diabetologia 30: 907-911.
47.
Vanderpump MP, Tunbridge WM (2002): Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid 12: 839-847.
48.
Wang C, Crapo LM (1997): The epidemiology of thyroid disease and implications for screening. Endocrinol Metab Clin North Am 26: 189-218.
50.
Jenkins RC, Weetman AP (2002): Disease associations with autoimmune thyroid disease. Thyroid 12: 977-988.
51.
Kabel PJ, Voorbij HA, de Haan M, et al. (1988): Intarthyroidal dendritic cells. J Clin Endocrinol Metab 66: 199-207.
52.
Weetman AP (2003): Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 148: 1-9.
53.
Michels AW, Eisenbatrh GS (2010): Immunologic endocrine disorders. J Allergy Clin Immunol 125 (Supp. 2): 226-237.
54.
Popko K, Osińska A, Kucharska A, Demkow U (2015): Cytometric analysis of perforin expression in NK cells, CD8+, and CD4+ lymphocytes in children with autoimmune Hashimoto’s thyroiditis - a preliminary study. J Pediatr Endocrinol Metab 28: 789-792.
55.
Baxter AG, Smyth NJ (2002): The role of NK cells in autoimmune disease. Autoimmunity 35: 1-14.
56.
Wencel B, Chow A, Schleusener H (1981): NK cell activity in autoimmune thyroid disorders. Proceedings of the 56th Annual Meeting of the American Thyroid Association Minneapolis Abstract T26.
57.
Lackner H, Urban C, Sovinz P, et al. (2008): Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children. Haematologica 93: 291-294.
58.
Fishman DN (2000): Hemophagocytic syndromes and infection. Emerging Infectious Diseases 6: 601-608.
59.
Henter JI, Horne AC, Arico M (2007): for the Histiocyte Society. Reviev HLH-2004: Diagnostic and therapeutic guidelines for Hemophagocytic Lymphohistiocytosis. Pediatr Blood Cancer 48: 124-131.
60.
Horne AC, Goransdotter Ramme K, Zheng C, et al. (2008): Charakterization of PRF1, STX1 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol 143: 75-83.
61.
Vastert SJ, van Wijk R, D’Urbano LE (2009): Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology 49: 441-449.
62.
Grom AA (2004): Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum 50: 689-698.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
